CF PharmTech, Inc. (02652.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 10.63

From 52W high−71.79%

Volume2.07M

Market capHKD 2.83B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 10.63

From 52W high

−71.79%

Volume

2.07M

Market cap

HKD 2.83B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

37.3

MomentumView details →

1D Return

+3.48%

YTD Return

−69.44%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+3.48%

YTD Return

−69.44%

1Y Return

—

RSI (14)

37.3

vs 50D SMA

−25.62%

vs 200D SMA

−54.93%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.00

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 3, 2027 →

Latest newsMore news →

Changfeng Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 210 million, up 2.1% year-on-year, gross profit of RMB 161 million, up 3.2%, and a net loss widening to RMB 10.51 million from RMB 1.23 million in the prior-year period, with no dividend declared.20d ago

Similar companies

ST交昂600530.SH Regencell Bioscience Holdings LimitedRGC Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.01349.HK 益佰制药600594.SH Supernus Pharmaceuticals, Inc.SUPN Hua Medicine (Shanghai) Ltd.02552.HK Find similar companies →

Latest newsMore news →

Changfeng Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 210 million, up 2.1% year-on-year, gross profit of RMB 161 million, up 3.2%, and a net loss widening to RMB 10.51 million from RMB 1.23 million in the prior-year period, with no dividend declared.20d ago